|
GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
EP2902030B1
(en)
|
2010-05-14 |
2016-09-14 |
Dana-Farber Cancer Institute, Inc. |
Thienotriazolodiazepine compounds for treating neoplasia
|
|
WO2011143660A2
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating leukemia
|
|
CN103180318B
(zh)
|
2010-05-14 |
2017-05-10 |
达那-法伯癌症研究所 |
雄性避孕组合物以及使用方法
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201106743D0
(en)
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2012151512A2
(en)
|
2011-05-04 |
2012-11-08 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
|
CA2870931A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Isoindolone derivatives
|
|
WO2013184878A1
(en)
|
2012-06-06 |
2013-12-12 |
Constellation Pharmaceuticals, Inc. |
Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
EP2858982A4
(en)
|
2012-06-12 |
2015-11-11 |
Abbvie Inc |
PYRIDINONE AND PYRIDAZINONE DERIVATIVES
|
|
WO2013192274A2
(en)
|
2012-06-19 |
2013-12-27 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
|
MX2015007921A
(es)
|
2012-12-21 |
2016-03-03 |
Zenith Epigenetics Corp |
Compuestos heterociclicos novedosos como inhibidores de bromodominio.
|
|
CN105377851B
(zh)
|
2013-03-11 |
2018-07-20 |
密执安州立大学董事会 |
Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
|
|
EP2968360B1
(en)
*
|
2013-03-14 |
2021-01-20 |
ConverGene LLC |
Quinolinone derivatives for the inhibition of bromodomain-containing proteins
|
|
WO2014140077A1
(en)
|
2013-03-14 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Furopyridines as bromodomain inhibitors
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
ES2704048T3
(es)
*
|
2013-03-14 |
2019-03-14 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
|
|
MX366703B
(es)
|
2013-03-15 |
2019-07-22 |
Incyte Holdings Corp |
Heterociclos tricíclicos como inhibidores de la proteína bet.
|
|
CA2901083A1
(en)
|
2013-04-26 |
2014-10-30 |
Beigene, Ltd. |
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
|
WO2015004534A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
CN105407888B
(zh)
*
|
2013-06-21 |
2019-05-21 |
齐尼思表观遗传学有限公司 |
新双环溴结构域抑制剂
|
|
AR096758A1
(es)
*
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
|
MX2015017963A
(es)
|
2013-06-28 |
2016-11-10 |
Abbvie Inc |
Inhibidores de bromodominio.
|
|
WO2015006193A1
(en)
|
2013-07-08 |
2015-01-15 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
CA2918910A1
(en)
|
2013-07-25 |
2015-01-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
EA035727B1
(ru)
*
|
2013-10-18 |
2020-07-31 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
WO2015074081A1
(en)
|
2013-11-18 |
2015-05-21 |
Bair Kenneth W |
Benzopiperazine compositions as bet bromodomain inhibitors
|
|
BR112016011024B1
(pt)
*
|
2013-11-18 |
2020-09-01 |
Forma Therapeutics, Inc |
Composto, composição farmacêutica, e, usos dos mesmos
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
LT3092227T
(lt)
*
|
2014-01-09 |
2018-08-10 |
Orion Corporation |
Bicikliniai heterocikliniai dariniai kaip bromodomeno inhibitoriai
|
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
KR20160115953A
(ko)
|
2014-01-31 |
2016-10-06 |
다나-파버 캔서 인스티튜트 인크. |
디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
|
|
JP2017504651A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体の使用
|
|
JP2017504650A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体およびその使用
|
|
WO2015131005A1
(en)
|
2014-02-28 |
2015-09-03 |
The Regents Of The University Of Michigan |
9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
|
|
CN106456653A
(zh)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
高胰岛素血症相关病症的治疗
|
|
SI3674302T1
(sl)
|
2014-04-23 |
2023-07-31 |
Incyte Holdings Corporation |
1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
|
|
PT3157928T
(pt)
|
2014-06-20 |
2019-05-30 |
Constellation Pharmaceuticals Inc |
Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida
|
|
JP2017526741A
(ja)
|
2014-08-08 |
2017-09-14 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体およびその使用
|
|
CN106793775B
(zh)
|
2014-08-08 |
2020-06-02 |
达纳-法伯癌症研究所股份有限公司 |
二氢碟啶酮衍生物及其用途
|
|
ES2705623T3
(es)
*
|
2014-09-12 |
2019-03-26 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de tetrahidroquinolina como inhibidores del bromodominio
|
|
ES2855225T3
(es)
|
2014-09-15 |
2021-09-23 |
Incyte Corp |
Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
|
|
SG11201703414VA
(en)
|
2014-10-27 |
2017-05-30 |
Tensha Therapeutics Inc |
Bromodomain inhibitors
|
|
CA2966303A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
CA2966298A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
EP3262045A1
(en)
|
2015-02-27 |
2018-01-03 |
The Regents of The University of Michigan |
9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
|
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
MX2017016337A
(es)
|
2015-06-26 |
2018-11-22 |
Tensha Therapeutics Inc |
Tratamiento de carcinoma de linea media nut.
|
|
EP3334725B1
(en)
|
2015-08-10 |
2025-04-23 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer
|
|
EA033679B1
(ru)
|
2015-09-02 |
2019-11-15 |
Glaxosmithkline Ip No 2 Ltd |
Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
|
|
HK1256419A1
(zh)
|
2015-09-11 |
2019-09-20 |
达纳-法伯癌症研究所股份有限公司 |
乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
|
|
PE20181287A1
(es)
|
2015-09-11 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
|
JP6795588B2
(ja)
|
2015-09-22 |
2020-12-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
|
|
ES2831322T3
(es)
|
2015-10-05 |
2021-06-08 |
Glaxosmithkline Ip No 2 Ltd |
Compuestos de 2-oxo-1,2-dihidropiridin-3,5-dicarboxamida como inhibidores de bromodominios
|
|
US20170121347A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
SG10201913450PA
(en)
|
2015-11-25 |
2020-03-30 |
Dana Farber Cancer Inst Inc |
Bivalent bromodomain inhibitors and uses thereof
|
|
ES2882066T3
(es)
|
2016-02-15 |
2021-12-01 |
Univ Michigan Regents |
1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
|
|
JP7001614B2
(ja)
|
2016-04-06 |
2022-02-03 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
リガンド依存性の標的タンパク質分解のための単官能性中間体
|
|
JP7037500B2
(ja)
|
2016-04-06 |
2022-03-16 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｍｄｍ２タンパク質分解剤
|
|
AU2017245641A1
(en)
|
2016-04-07 |
2018-09-13 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridyl derivatives as bromodomain inhibitors
|
|
WO2017174620A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Benzo[b]furans as bromodomain inhibitors
|
|
AU2017250076B2
(en)
|
2016-04-12 |
2021-07-22 |
The Regents Of The University Of Michigan |
Bet protein degraders
|
|
SG11201808003RA
(en)
|
2016-04-15 |
2018-10-30 |
Abbvie Inc |
Bromodomain inhibitors
|
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN109153646B
(zh)
|
2016-05-24 |
2022-08-02 |
葛兰素史克知识产权第二有限公司 |
作为溴结构域抑制剂的吡啶二甲酰胺衍生物
|
|
CR20190027A
(es)
|
2016-06-20 |
2019-05-16 |
Incyte Corp |
Formas sólidas cristalinas de un inhibidor de bet
|
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
AU2017326171B2
(en)
|
2016-09-13 |
2021-12-09 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
|
JP7035027B2
(ja)
|
2016-09-13 |
2022-03-14 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン
|
|
AU2017345468B2
(en)
*
|
2016-10-20 |
2022-06-02 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2018111805A1
(en)
*
|
2016-12-13 |
2018-06-21 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
WO2018144789A1
(en)
|
2017-02-03 |
2018-08-09 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet bromodomain inhibitors
|
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
|
US11267822B2
(en)
|
2017-09-13 |
2022-03-08 |
The Regents Of The University Of Michigan |
BET bromodomain protein degraders with cleavable linkers
|
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
|
TWI882964B
(zh)
|
2018-09-13 |
2025-05-11 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
|
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
治療前列腺癌之組合療法
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
CA3255932A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution As |
ACTIVE COMPOUNDS AGAINST BROMODOMAINS
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|